SCHEMBL141040

SCHEMBL141040

CC(=O)Nc1cc(Oc2ccc(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)c(F)c2)ccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 11/20 0.67
MAPK14 Q16539 9/20 0.67
KDR P35968 6/20 0.67
NTRK1 P04629 3/20 0.67
RIPK2 O43353 2/20 0.67
ABL1 P00519 2/20 0.67
LCK P06239 2/20 0.67
LYN P07948 2/20 0.67
RET P07949 2/20 0.67
HCK P08631 2/20 0.67
BCR P11274 2/20 0.67
EPHA2 P29317 2/20 0.67
FLT3 P36888 2/20 0.67
ABL2 P42684 2/20 0.67
FRK P42685 2/20 0.67
MST1R Q04912 2/20 0.67
DDR1 Q08345 2/20 0.67
MAP2K5 Q13163 2/20 0.67
PTK6 Q13882 2/20 0.67
DDR2 Q16832 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138396 0.89 MET (0.82) METMAPK14KDRNTRK1RIPK2
SCHEMBL2257051 0.87 KDR (0.72) METMAPK14KDRNTRK1RIPK2
SCHEMBL2250644 0.87 MET (0.76) METMAPK14KDRNTRK1RIPK2
SCHEMBL2251921 0.87 MET (0.76) METMAPK14KDRNTRK1RIPK2
SCHEMBL143451 0.87 MET (0.70) METMAPK14KDRNTRK1RIPK2
SCHEMBL2251520 0.86 MET (0.86) METMAPK14KDRNTRK1RIPK2
Hydrochloric Acid SCHEMBL3554723 0.86 MET (0.75) METMAPK14KDRNTRK1RIPK2
SCHEMBL139145 0.85 MET (0.59) METMAPK14KDRNTRK1RIPK2
SCHEMBL14742559 0.85 MET (0.58) METMAPK14KDRNTRK1RIPK2
SCHEMBL140837 0.85 MET (0.59) METMAPK14KDRNTRK1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150218130-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-08-06 US disclosed
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-07-10 US disclosed
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-07-10 US disclosed
EP-2563362-B1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS LLC (US) 2014-03-12 EP disclosed
EP-2563362-B1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS LLC (US) 2014-03-12 EP disclosed
US-8637672-B2 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-01-28 US disclosed
US-8637672-B2 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-01-28 US disclosed
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-12-20 US disclosed
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-12-20 US disclosed
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHAMACEUTICALS, LLC (US) 2012-10-04 US disclosed
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHAMACEUTICALS, LLC (US) 2012-10-04 US disclosed
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-03-08 US disclosed
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-03-08 US disclosed
WO-2011137342-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS, LLC (US) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885MAPK14 863/4885KDR 3640/4885
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885MAPK14 863/4885KDR 3640/4885
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885MAPK14 863/4885KDR 3640/4885
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885MAPK14 863/4885KDR 3640/4885
US-20150218130-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885MAPK14 863/4885KDR 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.